Creatinine
|
Basic information |
| Metabolite name | Creatinine |
 | HMDB0000562 |
 |
C00791 |
 |
588 |
| Synonyms | NA |
| No. of studies | 46 |
|
Basic information |
| Metabolite name | Creatinine |
| HMDB0000562 |
|
C00791 |
|
588 |
| Synonyms | NA |
| No. of studies | 46 |
|
Relationship between Creatinine and depression (count: 46) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M008 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M014 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M014 | Type2 | CUMS + XY-A group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M014 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
| Study M018 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M021 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M024 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M024 | Type2 | CUMS + middle dose of Xiaoyaosan group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M024 | Type2 | CUMS + fluoxetine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M024 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M032 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M032 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M032 | Type2 | CUMS + high dose of genipin group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M032 | Type2 | CUMS + venlafaxine group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M036 | Type1 | MDD group vs. control group | Urine | Human | Down |
| Study M043 | Type1 | chronic hepatitis B patients with MDD group vs. without MDD group | Urine | Human | Down |
| Study M045 | Type1 | CUMS group vs. control group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Up |
| Study M049 | Type2 | xiaoyansan treatment 8-week vs. baseline | Urine | Human | Up |
| Study M053 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Down |
| Study M053 | Type2 | CUMS + CSGS group vs. CUMS group | Urine | Wistar rat | Up |
| Study M062 | Type1 | CUMS group vs. control group | Cerebellum | Sprague-Dawley rat | Down |
| Study M071 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Down |
| Study M077 | Type1 | non-weaned FST group vs. weaned FST group | Urine | Wistar rat | Up |
| Study M077 | Type1 | non-weaned group vs. weaned group | Urine | Wistar rat | Up |
| Study M088 | Type3 | 6-h venlafaxine group vs. control group | Urine | Wistar rat | Down |
| Study M095 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M095 | Type2 | CUMS + XCHT group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M098 | Type1 | depressed group vs. control group | Peripheral blood mononuclear cell | Human | Down |
| Study M108 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M108 | Type2 | CUMS + VBBR group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M108 | Type2 | CUMS + BR group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M115 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M134 | Type1 | CRS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M134 | Type2 | CRS + BH group vs. CRS group | Urine | Sprague-Dawley rat | Up |
| Study M136 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M464 | Type1 | drug-naive MDD group vs. control group | Plasma | Human | Down |
| Study M464 | Type1 | drug-treatment MDD group vs. control group | Plasma | Human | Down |
| Study M480 | Type1 | sleep deprivation group vs. control group | Urine | Wistar rat | Up |
| Study M492 | Type1 | ACTH group vs. control group | Urine | Wistar rat | Down |
| Study M492 | Type2 | ACTH + CGA group vs. ACTH group | Urine | Wistar rat | Up |
| Study M492 | Type2 | ACTH + memantine group vs. ACTH group | Urine | Wistar rat | Up |
| Study M556 | Type1 | sleep deprivation group vs. control group | Urine | Wistar rat | Up |
| Study M577 | Type1 | female depression group vs. female control group, aged 30-39 | Urine | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 40-49 | Urine | Human | Unknown |
| Study M577 | Type1 | female depression group vs. female control group, aged 20-29 | Urine | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Plasma | Human | Unknown |
| Study M577 | Type1 | female depression group vs. female control group, aged 40-49 | Urine | Human | Unknown |
| Study M614 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M633 | Type1 | corticosterone group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M633 | Type2 | corticosterone + Chrysanthemum morifolium group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M712 | Type1 | depression group vs. control group | Liver | Cynomolgus monkey | Up |
| Study M740 | Type1 | CUMS group vs. control group | Soleus muscle | Sprague-Dawley rat | Up |
| Study M740 | Type1 | CUMS group vs. control group | Gastrocnemius muscle | Sprague-Dawley rat | Down |
| Study M740 | Type2 | CUMS + endurance exercise group vs. CUMS group | Soleus muscle | Sprague-Dawley rat | Down |
| Study M767 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M767 | Type2 | CUMS + HLJDD group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M775 | Type1 | prenatal stress group vs. control group | Brain | Swiss Webster mouse | Down |
| Study M779 | Type4 | remitter group vs. non-remitter group, at baseline | Plasma | Human | Up |
| Study M790 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M791 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M821 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M839 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M840 | Type1 | casein-rich milk group vs. control group | Urine | Wistar rat | Up |
| Study M846 | Type1 | postpartum depression model group vs. control group | Hippocampus | BALB/c mouse | Down |
| Study M846 | Type2 | postpartum depression model + 919 syrup group vs. postpartum depression model group | Hippocampus | BALB/c mouse | Down |
| Study M859 | Type2 | reserpine + hydrogel group vs. reserpine group | Hippocampus | Sprague-Dawley rat | Up |
| Study M859 | Type2 | reserpine + solution group vs. reserpine group | Hippocampus | Sprague-Dawley rat | Up |
| Study M906 | Type2 | after rTMS treatment vs. baseline | Cerebrospinal fluid | Human | Up |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Cerebrospinal fluid | Human | Up |
| Study M927 | Type2 | CUMS + Zhi-zi-chi decoction group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M953 | Type1 | CRS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |
| Study M965 | Type1 | CUMS depression group vs. control group | Faece | Sprague-Dawley rat | Up |